Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus conference.

× No keyword cloud information.

13 in total

1. Management of hepatocellular carcinoma.

Authors: Jordi Bruix; Morris Sherman
Journal: Hepatology Date: 2005-11 Impact factor: 17.425

2. Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis.

Authors: Christos S Georgiades; Kelvin Hong; Michael D'Angelo; Jean-Francois H Geschwind
Journal: J Vasc Interv Radiol Date: 2005-12 Impact factor: 3.464

3. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma.

Authors: Chung-Mau Lo; Henry Ngan; Wai-Kuen Tso; Chi-Leung Liu; Chi-Ming Lam; Ronnie Tung-Ping Poon; Sheung-Tat Fan; John Wong
Journal: Hepatology Date: 2002-05 Impact factor: 17.425

Review 4. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies.

Authors: Laura Marelli; Rosa Stigliano; Christos Triantos; Marco Senzolo; Evangelos Cholongitas; Neil Davies; Jonathan Tibballs; Tim Meyer; David W Patch; Andrew K Burroughs
Journal: Cardiovasc Intervent Radiol Date: 2007 Jan-Feb Impact factor: 2.740

5. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial.

Authors: Josep M Llovet; Maria Isabel Real; Xavier Montaña; Ramon Planas; Susana Coll; John Aponte; Carmen Ayuso; Margarita Sala; Jordi Muchart; Ricard Solà; Joan Rodés; Jordi Bruix
Journal: Lancet Date: 2002-05-18 Impact factor: 79.321

6. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics.

Authors: María Varela; María Isabel Real; Marta Burrel; Alejandro Forner; Margarita Sala; Mercé Brunet; Carmen Ayuso; Lluis Castells; Xavier Montañá; Josep M Llovet; Jordi Bruix
Journal: J Hepatol Date: 2006-11-29 Impact factor: 25.083

7. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.

Authors: Ann-Lii Cheng; Yoon-Koo Kang; Zhendong Chen; Chao-Jung Tsao; Shukui Qin; Jun Suk Kim; Rongcheng Luo; Jifeng Feng; Shenglong Ye; Tsai-Sheng Yang; Jianming Xu; Yan Sun; Houjie Liang; Jiwei Liu; Jiejun Wang; Won Young Tak; Hongming Pan; Karin Burock; Jessie Zou; Dimitris Voliotis; Zhongzhen Guan
Journal: Lancet Oncol Date: 2008-12-16 Impact factor: 41.316

8. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis.

Authors: Laura M Kulik; Brian I Carr; Mary F Mulcahy; Robert J Lewandowski; Bassel Atassi; Robert K Ryu; Kent T Sato; Al Benson; Albert A Nemcek; Vanessa L Gates; Michael Abecassis; Reed A Omary; Riad Salem
Journal: Hepatology Date: 2008-01 Impact factor: 17.425

Review 9. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival.

Authors: Josep M Llovet; Jordi Bruix
Journal: Hepatology Date: 2003-02 Impact factor: 17.425

10. Sorafenib in advanced hepatocellular carcinoma.

Authors: Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal: N Engl J Med Date: 2008-07-24 Impact factor: 91.245